As already touched upon, retrospective clinical data might hint to associations between SDF-1 polymorphisms or SDF-1/CXCR4 expression levels with susceptibility to neoplastic transformation, malignant progression or therapy response in a variety of tumor entities, such as renal cell carcinoma (97), prostate cancer (98), HNSCC (1, 100, 102, 113, 114), esophagogastric cancer (103), hepatocellular carcinoma (104), colorectal cancer (74), breast cancer (153), osteosarcoma (111), low grade glioma (154, 155), or GBM (156, 157). Here, CXCL12 is linked to breast cancer.